Stem cell research has been in process for over five decades. Stem cells have a unique ability to divide and replicate repeatedly, as well as an “unspecialized” nature that allows them to differentiate into a wide variety of specialized cell types. In a developing embryo, stem cells can differentiate into all of the embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.
Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Several broad categories of stem cells exist, including:
The possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells as research tools, to utilization in cell therapies and integration into 3D printed tissues and organs. Additionally, the ability to use stem cells to improve drug target validation and toxicology screening is of intense interest to the pharmaceutical industry.
Rapid Technological Innovation
As a result of this technological innovation, the stem cell industry is undergoing rapid change. As of July 2017, a search for stem cells yields the following results:
Undoubtedly, there is enormous interest surrounding the stem cell industry. However, this rapid technological changes leaves all industry participants wondering, what will be the future directions for the stem cell industry over the next 5, 10, or 15 years?
Interviews with Stem Cell Industry Executives
Founded in 2006, BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant is distinctively suited to tracking the stem cell marketplace, because it has been following the industry for a full decade (2006 to present). This rare attribute provides it with a robust 10-year database of historical information on which to base market predictions.BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine.
For the past decade, BioInformant has been interviewing stem cell industry executives, but this global strategic report represents the first time we have released them in entirety.
BioInformant is honored to launch this 166 page global strategic report featuring dozens of interviews with stem cell industry executives from leading companies worldwide, including the CEO of CDI (KazHirao), CEO of Gamida Cell (Dr Yael Margolin), President and Co-CEO of Pluristem Therapeutics (YakyYanay), and many more.
Within this global strategic report, leading stem cell executives discuss their product development strategies, intellectual property (IP) acquisition plans, manufacturing technologies, strategic collaborations, and much more. If you are competing within the stem cell industry, these insider insights are critical to staying at the forefront of an industry characterized by rapid innovation.
Table of Contents
Interview with Kaz Hirao, CEO of CDI, a FUJIFILM Company – Industrial Scale Production of iPSCs and Differentiated Cells 5
Interview with Dr. Yael Margolin, CEO of Gamida Cell - Solving the Unmet Need in Hematopoietic Stem Cell Transplantation (HSCT) 13
Interview with Dr. Frida Grynspan, VP of R&D for Stem Cell Medicine Ltd. - Developing Genetically Modified Muscle Progenitor Cells 21
Interview with Dr. Itzchak Angel, CEO of Accellta – Mass Production of Pluripotent Stem Cells 25
Interview with Eran Cohen, Intellectual Property (IP) Officer for Accellta – Small Company with the IP of a Big Company 32
Interview with Dr. Cynthia Bamdad, CEO of Minerva Biotechnologies - The Link Between Naïve Stem Cells and Cancer 35
Interview with Matthew Feshbach, Founder of Okyanos Cell Therapy (Part 1) - Adipose-Derived Stem Cell Therapies 40
Interview with Matthew Feshbach, Founder of Okyanos (Part 2) - Setting the Standard in Adipose-Derived Stem Cell Applications 46
Interview with Dr. Bruce Werber, COO of BPSR and CEO of Anu Life Sciences - Regenerative Applications of Placental Tissue Allografts 51
Interview with Dr. Ornella Parolini of IPLASS – Understanding Placental Stem Cell Applications 56
Interview with Pamela Levin of Tisch MS Research Center of NY– Beginning a Phase II Stem Cell Trial for MS 61
Interview with Dr. Saud Sadiq, Director of Tisch MS Research Center of NY - Stem Cells for Reversal of Multiple Sclerosis (MS) 66
Interview with James Alexis Mendez, CFO of CryoHoldco - Cord Blood Banking within Latin America 70
Interview with Kenneth Harris, Chief Advisor for CuraSense - Growth Rates & Trends within the Cord Blood Industry 74
Interview with Joseph Krieger of Boston Biolife - Educating Physicians about Regenerative Medicine 81
Interview with ORIG3N’s James Lovgren – Creating World’s Largest Blood Cell Repository for iPSC Production 87
Interview with Tony Veverka, Chief Group Executive of BioEden – How Dental Stem Cells Will Impact Our Future 90
Interview with João Andrade, CEO of WideCells Group – Unlocking the Future of Cord Blood Banking 93
Interview with Dr. Jon Rowley, Founder & CTO of RoosterBio - Radically Changing the Use of Stem Cells 96
Interview with Dr. Jon Rowley, Founder &CTO of RoosterBio - “Year of the Rooster” 101
Interview with Dr. Paul Wotton, Board Member of Cynata Therapeutics and Previous CEO of Ocata Therapeutics– Mass Production of Therapeutic Grade MSCs 109
Interview with Kyle Cetrulo, CEO of AuxoCell Laboratories – Future of Regenerative Medicine 115
Interview with Dr. Denver Lough, President and CEO of PolarityTE – Creating Functionally Polarized Tissue 120
Interview with Yaky Yanay, President and Co-CEO of Pluristem Therapeutics – Commercializing Placental Stem Cell Therapeutics 125
Interview with Dr. Priya Baraniak of RoosterBio - RM Industry’s First Xeno-free (XF) hMSC Cell Banks 134
Interview with Dr. Chris Centeno, CEO of Regenexx® – Orthopedic Applications of MSCs 137
Interview with Dr. Chris Centeno, CEO of Regenexx® - Visionary Behind Orthopedic Stem Cell Technology 143
Interview with Dr. Askenase of Yale University School of Medicine- MSC-Derived Exosomes for Spinal Cord Repair 153
Interview with Robin Smith, CEO of ORIG3N – Creating Patient-Specific iPSCs and a Living Database of Humanity 157
Make an enquiry before buying this Report
Please fill the enquiry form below.